Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NRG Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while NRG Energy Inc trades at $121.17 (market cap $24.83B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and NRG Energy Inc pays a 1.61% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NRG | |
|---|---|---|
Market Cap | $29.60B | $24.83B |
Sector | Health | Utilities |
52-Week High | $491.22 | $184.03 |
52-Week Low | $205.48 | $117.04 |
Enterprise Value | $27.56B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
NRG Energy trades at $120.37, down 1.23% with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.49 EPS versus $1.69 expected, though revenue grew 11% year-over-year. The company is advancing a 1.2 GW Texas data-center power project to capitalize on AI-driven electricity demand, supported by a 69% analyst buy rating and a $207.83 consensus price target. Cash flow from operations was $1.91B in 2025, but net income margin compressed to 2.56%.
Outlook is mixed: growth initiatives in data center power present upside, but execution risks and rising interest costs pressure margins. The stock offers a 1.6% dividend yield, yet high debt-to-asset ratio of 56.42% in 2025 warrants caution. Near-term support lies at $119, with resistance at $122.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
